News

Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis

PR Newswire · PR Newswire · last updated
According to industry estimates, the medical cannabis market in Europe is estimated to pass €1 billion in 2023. The Israeli medical cannabis market includes over 105,000 licensed patients and is estimated at $260 million per year, with over 60% of medical cannabis in Israel prescribed for pain and inflammation indications[3]. Based on these results, Canonic has filed a patent application for several of these cannabis varieties and their medical effects. The ability of Canonic’s medical cannabis varieties in reducing pain and inflammation in pre-clinical settings is impressive. The Company’s strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations.
View full article

here today, more tomorrow

We’ve launched briefing.center with a focus on the press and media.

And we’ve added Citizen Cartwright, a daily quick-read news summary by veteran Washington journalist Linda Cartwright. We’ve also created a new voting rights knowledge center for Citizen Cartwright subscribers. (You can sign up for a dedicated morning email at citizencartwright.com.)

You can sign up here for full access to press and media and Citizen Cartwright on briefing.center.

You can use briefing.center as the center of your information management, or just one of your tools. We’re happy to discuss your information needs.

Sign up